Induction of sulfadiazine resistance in vitro in Toxoplasma gondii

Experimental Parasitology

Volumn 133, Issue 2, 2013, Pages 131-136

  Doliwa, C ^a   Escotte Binet, S ^a,b   Aubert, D ^a,b   Velard, F ^c   Schmid, A ^a   Geers, R ^a,b   Villena, I ^a,b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c Plateforme d'Imagerie Cellulaire et Tissulaire   (France)

Author keywords

Drug resistance; In vitro; Sulfadiazine; Toxoplasma gondii

Indexed keywords

SULFADIAZINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH CURVE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; MICROBIAL GROWTH; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TACHYZOITE; TOXOPLASMA GONDII; VERO CELL;

ANIMALS; ANTIPROTOZOAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INHIBITORY CONCENTRATION 50; PARASITIC SENSITIVITY TESTS; SULFADIAZINE; TOXOPLASMA; VERO CELLS;

TOXOPLASMA GONDII;

EID: 84871400764     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.11.019     Document Type: Article

References (16)

1. Aspinall T.V., Joynson D.H., Guy E., Hyde J.E., Sims P.F. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 2002, 185(11):1637-1643.
2. Baatz H., Mirshahi A., Puchta J., Gumbel H., Hattenbach L.O. Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 2006, 14:185-187.
3. Dannemann B., McCutchan J.A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J., Vilde J.L., Orellana M., Feigal D., Bartok A., Heseltine P., Leedom J., Remington J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann. Intern. Med. 1992, 116(1):33-43.
4. De Oliveira T.C., Silva D.A., Rostkowska C., Béla S.R., Ferro E.A., Magalhães P.M., Mineo J.R. Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. Exp. Parasitol. 2009, 122(3):233-241.
5. Derouin F., Chastang C. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob. Agents Chemother. 1988, 32(3):303-307.
6. Derouin F., Chastang C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob. Agents Chemother. 1989, 33(10):1753-1759.
7. Ishikawa Y., Kozakai T., Morita H., Saida K., Oka S., Masuo Y. Rapid detection of mycoplasma contamination in cell cultures using SYBR Green-based real-time polymerase chain reaction. In Vitro Cell. Dev. Biol. Anim. 2006, 42(3-4):63-69.
8. Jin C., Kaewintajuk K., Jiang J., Jeong W., Kamata M., Kim H.S., Wataya Y., Park H. Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp. Parasitol. 2009, 121(2):132-136.
9. Katlama C., Mouthon B., Gourdon D., Lapierre D., Rousseau F. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. AIDS 1996, 10(10):1107-1112.
10. Meneceur P., Bouldouyre M.A., Aubert D., Villena I., Menotti J., Sauvage V., Garin J.F., Derouin F. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob. Agents Chemother. 2008, 52(4):1269-1277.
11. Petersen E. Prevention and treatment of congenital toxoplasmosis. Expert Rev. Anti Infect. Ther. 2007, 5(2):285-293.
12. Pfefferkorn E.R., Borotz S.E., Nothnagel R.F. Toxoplasma gondii: characterization of a mutant resistant to sulfonamides. Exp. Parasitol. 1992, 74(3):261-270.
13. Saadatnia G., Haj Ghani H., Khoo B.Y., Maimunah A., Rahmah N. Optimization of Toxoplasma gondii cultivation in VERO cell line. Trop. Biomed. 2010, 27(1):125-130.
14. Sander J., Midtvedt T. Development of sulphonamide resistance in Toxoplasma gondii. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 1971, 79(4):531-533.
15. Torres R.A., Weinberg W., Stansell J., Leoung G., Kovacs J., Rogers M., Scott J. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 1997, 24(3):422-429.
16. Van der Ven A.J., Schoondermark-van de Ven E.M., Camps W., Melchers W.J., Koopmans P.P., Van der Meer J.W., Galama J.M. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J. Antimicrob. Chemother. 1996, 38(1):75-80.